Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

167.81 -1.40 (-0.83%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
News headline image
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies ↗
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Expert Ratings for Charles River ↗
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
News headline image
5 Analysts Have This to Say About Charles River ↗
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
News headline image
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
News headline image
Where Charles River Stands With Analysts ↗
Charles River (NYSE:CRL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Expert Ratings for Charles River ↗
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Charles River Q2 Earnings ↗
  Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022 ↗
Upgrades 
Via Benzinga
News headline image
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
News headline image
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Charles River Laboratories Expands Contract Vivarium Space on West Coast
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks ↗
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
News headline image
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
From Charles River Laboratories, International Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday ↗
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
News headline image
Charles River Laboratories Announces Second-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL). 
Via Benzinga
News headline image
Where Charles River Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Charles River (NYSE:CRL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
From Charles River Laboratories International, Inc.
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS